Eagle Pharmaceuticals Inc

EGRX
4,05
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 11:53:07
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/3/202422:49EDGAR2Form 8-K - Current report
01/3/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202413:35EDGAR2Form 8-K - Current report
01/3/202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202414:09EDGAR2Form 8-K - Current report
14/2/202423:09EDGAR2Form SC 13D - General statement of acquisition of beneficial..
13/2/202421:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:50EDGAR2Form 8-K - Current report
09/2/202411:45PRNUSEagle Pharmaceuticals, Inc. Securities Fraud Class Action..
07/2/202415:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202411:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
26/1/202411:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
19/1/202411:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
18/1/202412:56EDGAR2Form 8-K - Current report
18/1/202412:50GLOBEEagle Pharmaceuticals Provides Update on Bendamustine..
16/1/202413:00EDGAR2Form 8-K - Current report
12/1/202411:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
09/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202411:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
23/12/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:15EDGAR2Form 8-K/A - Current report: [Amend]
20/12/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202311:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
15/12/202323:11EDGAR2Form 8-K - Current report
06/12/202322:26EDGAR2Form 8-K - Current report
06/12/202322:05GLOBEEagle Pharmaceuticals to Present Abstract on Post-hoc..
29/11/202313:39EDGAR2Form 8-K - Current report
29/11/202313:36EDGAR2Form 8-K - Current report
09/11/202323:23EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
09/11/202313:57EDGAR2Form 8-K - Current report
09/11/202313:30GLOBEEagle Delays Third Quarter 2023 Results and Conference Call
08/11/202314:30GLOBEEagle Pharmaceuticals to Host Third Quarter 2023 Financial..
03/11/202321:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:53EDGAR2Form 144 - Report of proposed sale of securities
01/11/202322:02EDGAR2Form 144 - Report of proposed sale of securities
31/10/202322:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202314:49EDGAR2Form 8-K - Current report
24/10/202314:40GLOBEEagle Pharmaceuticals Granted Patent for PEMFEXY®
23/10/202313:10EDGAR2Form 8-K - Current report
23/10/202312:50GLOBEEagle Pharmaceuticals Granted Unique J-Code and Pass-Through..
04/10/202323:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202312:50GLOBEEagle Pharmaceuticals Awarded First Prize for Poster to Be..
03/10/202322:48EDGAR2Form 144 - Report of proposed sale of securities
02/10/202322:51EDGAR2Form 144 - Report of proposed sale of securities
27/9/202313:00EDGAR2Form 8-K - Current report
19/9/202322:05GLOBEEagle Pharmaceuticals to Present at the Cantor Global..
11/9/202312:50GLOBEEagle Pharmaceuticals to Present CAL02 Trial in Progress at..
Apertura: Min: Max:
Chiusura: 4,05

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network